Organisation paid for research Program year 2025 Source: CMS Open Payments

Abington Hematology Oncology Associates, Inc

Neither a doctor nor a teaching hospital

Research payments

$54,510

39 payments

Through program year 2025, Abington Hematology Oncology Associates, Inc is reported as receiving $54,510 in research payments, across 39 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$258	1
2024	Research	$3,485	6
2022	Research	$14,870	6
2021	Research	$19,505	13
2020	Research	$5,928	8
2019	Research	$10,463	5

Breakdown

Who paid Research payments · program years 2019–2025

Eli Lilly and Company $54,510 39 payments

Studies the money was for Research payments · program years 2019–2025

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $25,718 7 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease $9,107 3 payments
Assessment of Safety, Tolerability and Efficacy of Ly3002813 Alone and in Combination With Ly3202626 in Early Symptomatic Alzheimers Disease $8,496 3 payments
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-Avwa in Participants With Early Symptomatic Alzheimer's Disease $2,593 2 payments
Randomized, Placebo Controlled, Phase 2 Clinical Trial to Evaluate Ly3556050 for the Treatment of Osteoarthritis Pain $1,252 1 payment
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (Lucent 2) $1,210 3 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (Lucent 1) $1,144 1 payment
A Study of Retatrutide (Ly3437943) on Renal Function in Participants With Overweight Or Obesity and Chronic Kidney Disease With Or Without Type 2 Diabetes $1,108 1 payment
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis Lucent 3 $1,078 5 payments
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer $808 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.